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We have previously reported  that virulent egg yolk-grown Legionella pneumophila, 
Philadelphia 1 strain, multiplies intracellularly in human blood monocytes and only 
intracellularly under tissue culture conditions (1). Because this bacterium can multiply 
extracellularly on complex media, L. pneumophila is a facultative intracellular parasite. 
Patients with Legionnaires' disease respond to the infection by producing antibody 
against L. pneumophila. In  fact, the diagnosis of Legionnaires' disease is most often 
made serologically by demonstrating a rise in antibody titer to L. pneumophila during 
the course of the disease. However, the role of antibody in prevention or control of the 
disease has not been defined. 
In this study, we have examined the interaction between virulent egg yolk-grown 
L. pneumophila and  human  polymorphonuclear leukocytes (PMN), 1 antibody,  and 
complement in vitro under antibiotic-free conditions. We shall demonstrate that L. 
pneumophila bacteria are resistant to the bactericidal effects of serum and that these 
bacteria,  even  when  coated  with  antibody  and  complement,  are  only  partially 
susceptible to killing by PMN. These findings suggest that PMN, even in conjunction 
with the humoral immune system, do not play a decisive role in defense against the 
Legionnaires' disease bacterium. 
Materials and Methods 
Media.  Egg yolk buffer (EYB), EYB that contained 1% bovine serum albumin (EYB-BSA), 
Hanks' balanced salt  solution  (HBSS),  Dulbecco's phosphate-buffered saline with Ca ++ and 
Mg  +÷ ions (PBS), and RPMI  1640 medium were obtained or prepared as described previously 
(1, 2). No antibiotics were added to any medium in any of the experiments. 
Agar.  Modified  charcoal  yeast  extract  agar  (CYE  agar)  was  prepared  in  100-  ×  15-mm 
bacteriologic Petri dishes as described (1). 
Antisera.  Goat  anti-human  complement  C3,  IgG  fraction,  rhodamine-conjugated  (N.  L. 
Cappel  Laboratories,  Inc.,  Coehranville,  Pa.);  rabbit  anti-L, pneumophila,  Knoxville  1 strain, 
* Supported by grant AI 08697  from the National Institutes of Health. 
:~ This work was performed while Dr.  Horwitz was a  U. S. Public Health Service  postdoctoral fellow 
(fellowship  AI 05629). 
I Abbreviations used in this paper." CFU, colony-forming units; CYE agar, modified charcoal yeast extract 
agar; EYB, egg yolk buffer; EYB-BSA,  egg yolk buffer that contained 1% bovine serum albumin; HBSS, 
Hanks' balanced salt solution; IFA, indirect fluorescent antibody assay;  PBS,  phosphate-buffered saline 
with Ca  ++ and Mg  +÷ ions; PMN, human polymorphonuclear leukocytes. 
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(Group 1) antiserum, globulin fraction, and fluorescein-conjugated globulins from the same lot, 
were obtained from the Center for Disease Control, U. S. Public Health Service, Atlanta, Ga. 
The nonconjugated antiserum was diluted  1:9 in PBS and dialyzed three times against  100 
volumes of PBS; 0.6 #1 of this antiserum preparation agglutinated 1 ml of a  suspension of L. 
pneumophila (prepared  by culturing egg  yolk-grown organisms for  72  h  on  CYE  agar  and 
Suspending the bacteria in EYB at a  concentration of 0.30 OD U  at A~0 nm on a Coleman 44 
spectrophotometer  [Perkin-Elmer Corp.,  Instruments Div., Norwalk, Conn.]). Consequently, 
0.6 #1 of this antiserum preparation is referred to in this paper as  1 agglutinating U. In our 
studies, we used 8.5 agglutinating U/ml; at the concentrations of L. pneumophila (<_ 106 colony- 
forming units [CFU]/ml) used in our studies, this amount of antibody did not agglutinate the 
bacteria. 
Serum.  Venous blood was obtained, clotted, and serum separated and stored at -70°C until 
used as described (2).  Normal human serum with an indirect fluorescent antibody (IFA) anti- 
L. pneumophila titer of<1:64 (3) was obtained from an adult donor not known to have ever had 
Legionnaires' disease. Immune human serum with an IFA anti-L, pneumophila titer of 1:4,096 
was obtained from an adult donor who had recently recovered from Legionnaires' disease; Dr. 
John Marr of the New York City Department of Health kindly assisted in locating this person. 
Ms. Helen Kravitz of the New York City Department of Health and Dr. Karim Hechemy of 
the  New  York  State  Health  Department,  Albany,  N.  Y.  determined  serum  IFA  anti-L. 
pneumophila titers. 
Complement was inactivated by heating the serum at 56°C for 30 min just before use. 
Bacteria.  L.  pneumophila Philadelphia  1  strain  were  grown  in  embryonated  hens'  eggs, 
harvested, tested for %'iability and for the presence of contaminating bacteria, stored at -70°C, 
and partially purified by differential eentrifugation just before use, as described (1).  A single 
batch was used in all experiments. 
Escherichia coli, serotype 09:K29:H-, strain Bi 161-42, an encapsulated, serum-resistant strain 
(2), was cultured and prepared for experiments as described (2). 
Human PMN.  Blood from a single healthy donor (type AB  +) was collected in a heparinized 
syringe and mixed  h l  with 0.9% sodium chloride  (normal saline); PMN were separated  by 
centrifugation over a discontinuous gradient of Ficoll and sodium diatrizoate by the method of 
English  and  Anderson  (4).  Residual  erythrocytes  were  hypotonically lysed  and  isotonicity 
restored  as  described  (2).  PMN  were  resuspended  in HBSS,  counted,  and  adjusted  to  the 
required concentration; their viability was >99%  as measured by trypan blue exclusion (2). 
The cells (>99% PMN) were used within 30 min of purification. 
Serum Bactericidal Activity for L. pneumophila.  L. pneumophila in concentrations ranging from 
10  n to  10  n CFU/ml were incubated in 0,  10, 25, or 50%  fresh normal human serum in plastic 
test tubes (0.4 ml final vol) for 1 h at 37°C on a gyratory shaker at 250 rpm. In experiments in 
which serum bactericidal activity was measured in the presence of antibody, 8.5 agglutinating 
U/ml  (see  above)  of dialyzed rabbit  anti-L, pneumophila antiserum or  20%  heat-inactivated 
immune human serum was added to test tubes that contained the bacteria and serum. At the 
end of the incubation, the contents of each tube were serially diluted in EYB-BSA and CFU of 
L. pneumophila were determined on CYE agar as described (1). 
Complement Fixation to the L. pneumophila Surface.  3 ×  106 CFU ofL. pneumophila was incubated 
for 15 min at 37°C in 600/xl of medium that contained 25% fresh normal human serum, 25% 
fresh  immune  human  serum,  25%  heat-inactivated  immune  human  serum,  or  25%  heat- 
inactivated immune human serum plus 25% fresh normal human serum. In some experiments, 
8.5 agglutinating U/ml of dialyzed, noneonjugated rabbit antiserum were  added  instead of 
heat-inactivated immune human serum. The bacteria were then washed twice with PBS (4°C) 
and  incubated with  rhodamine-conjugated goat  anti-human C3  IgG  as  described  (2).  The 
bacterial suspension was  then air-dried on glass slides,  incubated with  10/~1 of fluorescein- 
conjugated rabbit anti-L, pneumophila antiserum for 20 min at 37°C in a  humidified chamber, 
washed, incubated for i0 min at 22°C in phosphate-buffered saline (pH 7.6)  (5), air dried, and 
examined  with  a  Zeiss  Fluorescent  Photomicroscope  III  (Carl  Zeiss,  Inc.,  New  York).  L. 
pneumophila bacteria were  first  identified by fluorescein fluorescence and then these bacteria 
were examined for the presence of C3 on their surfaces by rhodamine fluorescence. 
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incubated with antibody at 37°C for 15 min in the presence or absence of fresh normal human 
serum.  This was determined  by fluorescence microscopy, using fluorescein-conjugated rabbit 
anti-L, pneumophila antiserum. 
Capacity of PMN to Bind or to Ingest L. pneumophila.  5  ×  106 PMN and  5  ×  105 CFU of L. 
pneumophila were added  to plastic tubes that  contained  10% fresh normal  human  serum,  10% 
fresh immune human serum, or 10% heat-inactivated immune human serum. The tubes were 
brought  to a  final vol of 900/tl with HBSS, gassed with 5% CO2-95% air so that  the pH was 
7.4,  as judged  by  the  color of the  phenol  red  indicator  dye,  capped,  sealed  with  Parafilm 
(American  Can  Co.,  Greenwich,  Conn.),  and  incubated  for  30  min  at  37°C  on  a  gyratory 
shaker at 250 rpm. At the end of the incubation, the tubes were placed in an ice-water bath to 
stop the reaction, and the cells were centrifuged onto glass slides using a  sealed cytocentrifuge 
specimen  container  especially  designed  for  use  with  biohazardous  material  (Cytospin  and 
Accessories, Shandron  Southern  Instruments,  Inc., Sewickley, Pa.).  The cells were fixed with 
Diff-Quick Fixative  (Harleco,  American  Hospital  Supply  Corp.,  Gibbstown,  N. J.),  stained 
with fluorescein-conjugated rabbit anti-L, pneumophila antiserum as described (1), and examined 
by fluorescence microscopy. The percentage of 200 consecutive PMN with associated bacteria, 
and the average number of bacteria/PMN were determined. 
For electron microscopy, PMN and bacteria were incubated together at the same ratio and 
under the same conditions as described above. The cells were fixed and processed for electron 
microscopy essentially as described (1) except that they were centrifuged into 2% agarose before 
dehydration and embedding. The sections were stained with lead citrate and uranyl acetate (1) 
and  examined  with  a  Philips  300  electron  microscope  (Philips  Electronic  Instruments,  Inc., 
Mahwah, N. J.). 
PMN-killing Assay.  In all killing assays, reactants  (total vol 900 p.l) were added sequentially 
to plastic tubes. The tubes were gassed with 5% CO2-95% air (final pH of contents of each tube 
-- 7.4), sealed, and incubated for 1, 2, or 3 h as described above under capacity of PMN to bind 
or ingest L. pneumophila. L. pneumophila (2.5  ×  10  s or 5 X  10  s CFU) and/or E. coli (5 ×  10  s CFU) 
in  100 p,I HBSS, the serum preparation  (90 #1 fresh normal human serum, 90 #! fresh immune 
human  serum,  90 #1  heat-inactivated  immune human  serum plus 90 #1  fresh normal  human 
serum, or 4.5 #1 of dialyzed rabbit anti-L, pneumophila antiserum  [8.5  agglutinating U/ml] plus 
90 #1 fresh normal human serum)  and enough PBS to bring the vol to 400 #1 were added first 
and incubated  10 min at 22°C. Then 2.5 or 5 X  106 PMN in 500 p,l HBSS (or the sonicate from 
an  equivalent number  of PMN or HBSS alone as controls)  were added  to each  tube,  after 
which  the  tubes  were  gassed,  sealed,  and  incubated.  A  separate  tube  was  used  for  each 
measurement;  thus tubes were not opened until  the end of the incubation.  At that  time, the 
tubes were placed in an  ice-water bath  to stop the reaction, and the contents were sonicated 
under sterile conditions for 15 sec continuously with a micro-tip attached to a sonicator (Heat- 
Systems Ultrasonics,  Inc., Plainview, N. Y.)  set  at  the 3  position;  this amount  of energy was 
sufficient to lyse the PMN completely but did not reduce bacterial CFU (1, 2). The CFU of L. 
pneumophila on CYE agar and ofE. coli on tryptic soy broth agar or CYE agar were determined 
as described  (1,  2); E.  coli grew equally well on both  nutrient  agars,  but  L. pneumophila grew 
only on CYE agar. 
Separation of PMN-associated and Nonassociated L. pneumophila by Differential Centrifugation.  PMN 
and  L. pneumophila were incubated  with  normal  human  serum  or immune  human  serum  as 
described above under PMN-killing assay. At the end of the incubation,  9.1  ml of PBS (4°C) 
was  added  to  each  tube,  and  the  contents  transferred  to  a  conical  centrifuge  tube  and 
centrifuged at 45 g  for  10 rain at 4°C. When PMN were mixed with L. pneumophila at 4°C in 
medium that  contained normal  human  serum and centrifuged under these conditions, >99% 
of PMN were pelleted but >99% of L. pneumophila remained in the supernate.  The supernate 
was removed and  the pellet was resuspended  in  2  ml PBS.  The  supernate  and  resuspended 
pellet were then sonicated as described above under PMN-killing assay and the total CFU in 
the  pellet  and  supernatant  fractions  determined.  Three  replicate  tubes  were  used  for  each 
measurement with immune serum and two replicate tubes for each measurement with normal 
serum.  Additional  replicate  tubes,  the  contents  of which  were  not  fractionated  after  the 
incubation, were used to measure killing ofL. pneumophila as in the PMN-killing assay described 
above; two tubes were used for each measurement. MARCUS  A,  HORWITZ  AND  SAMUEL  C.  SILVERSTEIN  389 
Results 
L. pneumophita Is Resistant to the Bactericidal Effects of Serum Even in the Presence of High 
Concentrations of Antibody.  We incubated  103-106 CFU/ml L. pneumophila in medium 
that contained various concentrations of fresh normal human serum (lacking antibody 
to L. pneumophila by the IFA assay) for 1 h  at 37°C on a  gyratory shaker. There was 
no reduction in CFU of L. pneumophila (Table I A). Similarly, when we incubated L. 
pneumophila in medium that contained 0-50% fresh normal human serum and either 
8.5  agglutinating  U/ml of rabbit  anti-L, pneumophila antiserum  (Table I B)  or 20% 
heat-inactivated immune human serum (Table I C), the CFU of L. pneumophila were 
not reduced. The fresh normal human serum used in these experiments reduced CFU 
of a serum-sensitive strain of Neisseria gonorrhea by >4 logs. 
Thus, virulent egg yolk-grown L. pneumophila are resistant to the bactericidal effects 
of human serum even in the presence of high concentrations of rabbit or human anti- 
L. pneumophila antibody. 
Antibody Is Required to Fix Complement to the Surface of L. pneumophila.  To determine 
whether anti-L, pneumophila antibody is required to fix complement to the surface of 
L. pneumophila, we incubated these bacteria with fresh normal human serum (a source 
of complement)  in  the  presence  and  absence of heat-inactivated  human  or  rabbit 
immune serum (sources of anti-L, pneumophila antibody) or with fresh immune human 
serum.  We  assayed  complement  fixation  to  the  bacterial  surface  by  fluorescence 
microscopy, using rhodamine-conjugated  goat anti-human  C3  IgG to visualize this 
complement  component.  To  facilitate  identification  of all  the  bacteria,  we  then 
incubated the bacteria with fluorescein-conjugated rabbit anti-L, pneumophila antise- 
rum. 
Over 90%  of L. pneumophila bacteria  fixed  C3  to  their  surfaces, as evidenced  by 
rhodamine fluorescence, after incubation with a source of both antibody and comple- 
ment. None of the L. pneumophila exhibited rhodamine fluorescence after incubation 
with antibody or complement alone. However, the intensity of fluorescence exhibited 
by L. pneumophila after incubation with high-titer specific antibody (human or rabbit) 
and  complement  was  weak  in  comparison  to  that  exhibited  by  a  serum-resistant 
encapsulated  strain of E. coli (E. coli 09:K29:H-)  (2).  This suggests that  the anti-L. 
pneumophila antibodies found in human immune serum or in rabbit antiserum are not 
capable of fixing as much C3 to the surface of L. pneumophila as human  anti-E,  coli 
antibodies are capable of fixing to the surface of the E. coli strain. 
PMN  Phagocytose  L.  pneumophila  Only  in  the  Presence  of  Both  Antibody  and 
Complement.  We incubated  PMN with L. pneumophila in the presence of serum that 
contained anti-L, pneumophila antibody and/or complement. We then centrifuged the 
PMN onto glass slides, stained the PMN-associated bacteria with fluorescein-conju- 
gated  rabbit  anti-L,  pneumophila antiserum,  and  examined  them  by  fluorescence 
microscopy (Table II). 
With  complement alone or antibody alone, few PMN  (21  and  14%, respectively) 
bound or ingested L. pneumophila, and those that did had an average of less than two 
bacteria/PMN  (Table  II).  With  both  antibody  and  complement,  93.5%  of PMN 
bound or ingested  L. pneumophila; these had an average of 5.1  L. pneumophila/PMN 
(Table II and Fig.  1 A). 
In these experiments, the ratio of bacterial eells:PMN was ~5:1.  (The CFU:PMN 
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TABLE  I 
Viability of L. pneumophila in the Presence  of Human Serum and Rabbit or 
Human Anti-L. pneumophila Antibody 
(A) Viability in the presence of fresh normal human serum 
Initial number of 
L. pneumophila 
Number ofL. pneumophila after a  1-h incubation in 
medium that contained 0-50% serum 
0%  10%  25%  50% 
CFU/ml  CFU/ml 
4.0 X  106  3.4 ×  105  3.8 ×  106  4.9 x  106  5.6 X  106 
3.2 X  105  3.6 ×  105  6.3 ×  105  6.1 ×  105  3.8 ×  105 
4.7 X  104  1.6 X  104  5.6 X  104  5.8 ×  104  6.3 ×  t04 
1.3 ×  103  1.7 ×  103  2.5 ×  10  a  3.1  ×  103  3.1  ×  103 
(B) Viability in the presence of fresh normal human serum and rabbit anti- 
L. pneumophila antiserum 
Number of L. pneumophila after a  l-h incubation in 
medium that contained 0-50% serum and 8.5 aggluti-  Initial number of 
L. pneumophila  nating doses/ml anti-L, pneumophila antiserum 
0%  10%  25%  50% 
CFU/ml  CFU/ml 
1.0 x  105  1.2 x  106  0.9 x  [05  2.6 ×  105  5.4 ×  105 
1.1 ×  104  0.6 ×  104  3.6 ×  I04  2.8 ×  104  4.2 ×  104 
1.8 ×  10  3  0.9 X  10  3  1.2 ×  tO  3  2.6 ×  10  3  2.1  ×  IO  s 
4.6 ×  I0  2  1.6 ×  lO  2  3.4 ×  I0  2  5.6 X  10  2  4.0 ×  lO  z 
(C) Viability in the presence of fresh normal human serum and heat- 
inactivated immune human serum 
Initial number of 
L. pneumophila 
Number of L. pneumophila after a  1-h incubation in 
medium that contained 0-50% serum and 20% heat- 
inactivated immune human serum 
0%  10%  25%  50% 
CFU/ml  CFU/ml 
2.7 ×  106  2.7 ×  10  °  2.4 ×  106  3.0 ×  106  2.1  ×  l06 
3.2 ×  10  ~  3.1  ×  10"  2.8 x  105  3.5 X  105  2.9 ×  105 
2.7 ×  104  3.6 ×  104  3.1  ×  104  3.4 ×  104  3.1  ×  104 
2.8 ×  103  3.1  x  103  2.8 X  103  3.0 x  103  2.8 ×  10  a 
L. pneumophila at the indicated concentrations of CFU/ml were incubated for 
1 h at 37°C on a  gyratory shaker in medium that contained 0,  10, 25, or 50% 
fresh normal human serum anc'l (A) No antibody, (B) 8.5 agglutinating doses/ 
ml of dialyzed rabbit anti-L, pneumophila antiserum, or (C) 20% heat-inactivated 
immune human serum with an IFA anti-L, pneumophila titer of 1:4,096. CFU 
were determined initially and at the end of the incubation. 
in  egg  yolk-grown  cultures  [6]).  That  PMN  bound  or  ingested  an  average  of  4.75 
bacterial  cells  in  the  presence  of antibody  and  complement  (Table  II)  indicates  that 
nearly  all the  bacterial  cells in  the culture  were  bound  to or ingested  by  PMN  under 
these conditions.  That  this conclusion  is valid  for viable  bacteria  is supported  by  our 
finding  (Fig.  4 B)  that  nearly  all the  viable  L. pneumophila  in  the culture  are bound  to 
or ingested  by  PMN  in the  presence  of antibody  and  complement. MARCUS A.  HORWITZ AND SAMUEL C.  SILVERSTEIN 
TABLE II 
Capacity of PMN to Bind or to Ingest L. pneumophila in the Presence of Antibody 
and/or Complement 
391 
Serum preparation 
Percentage of  Average  num- 
ber of L. pneu-  Index of PMN- 
PMN binding  or  mophila/PMN  L. pneumophila 
ingesting L. pneu-  with ~1 associ-  association* 
mophila  ated bacteria 
Normal serum  21  1.2  25 
Heat-inactivated  14  1.8  25 
immune serum 
Fresh immune serum  93.5  5.1  475 
5 X l0  s PMN and 5 ×  105 CFU of L. pneumophila (~2.5 X 107 bacterial particles) 
were incubated in the presence of 10% of the indicated serum preparation for 30 
rain at  37°C on a gyratory shaker. At the end of the incubation, the cells were 
cytocentrifuged on to glass slides, fixed, stained with fluorescein-conjugated  rabbit 
anti-L, pneumophila  antiserum, examined by fluorescence  microscopy,  and 20 consec- 
utive PMN counted. 
* The index of PMN-L. pneumophila association is the percentage of PMN with bound 
or ingested L. pneumophila multiplied by the average number  ofL. pneumophila/PMN 
with ~ 1 associated bacteria. 
To determine whether  PMN  phagocytosed  L.  pneumophila when  incubated with 
them in the presence of antibody and complement, we examined the cells by electron 
microscopy. We found 25 PMN-associated L. pneumophila upon examination of ~200 
leukocyte profiles. Of these, 23 were intracellular (Fig. 1 B and C) and 2 were adhered 
to the surface of PMN  (and appeared  fixed in the process of being ingested). This 
indicates that in preparations of PMN incubated with L. pneumophila in the presence 
of both antibody and complement (Table II), most of the PMN-associated bacteria 
were intracellular. 
These results and our finding that antibody was required to fix complement to L. 
pneumophila, indicate that PMN effectively phagocytose L. pneumophila only if comple- 
ment is fixed to the bacterial surface. 
PMN Require Both Antibody and Complement to Kill Any L. pneumophila.  We incubated 
PMN  with  L.  pneumophila  in  the  presence  of  fresh  normal  human  serum,  heat- 
inactivated immune human serum (data not shown), or fresh immune human serum 
(Fig.  2).  PMN  killed L.  pneumophila only when  both  a  source of antibody and  of 
complement were present  (Fig. 2).  Even then, PMN reduced CFU of L. pneumophila 
by only 0.5 log (70%)  (five experiments). Increasing the ratio of PMN:L. pneumophila 
from  10:1  to 20:1  or to 40:1  or the percentage of immune human serum from  10 to 
20%  or  40%  did  not  improve  PMN  killing of L.  pneumophila. Most  of the  killing 
occurred in the  1st h  of incubation (Fig. 4 B). Some additional killing occurred when 
the  incubation was  extended  from  1  to  4  h  (Fig.  4B),  but  no  additional killing 
occurred when the incubation was further extended from 4 to 6 h  (data not shown). 
L. pneumophila Resists Killing by PMN under Conditions in  Which PMN Effectively Kill a 
Serum-resistant Encapsulated Strain orE. coli.  To compare PMN killing of L. pneumophila 
with  PMN  killing of a  serum-resistant encapsulated strain of E.  coli, we  incubated 
PMN with E. coli alone, L. pneumophila alone, or both types of bacteria in the presence 
of fresh  normal human serum with or without a  source of rabbit or human anti-L. 
pneumophila antibody (Fig. 3).  In the experiment described in Fig. 3, we used rabbit 392  LEGIONELLA PNEUMOPHILA RESISTS KILLING  BY  POLYS 
FIG.  1.  PMN bind and  ingest  L. pneumophila in  the presence  of antibody and complement.  (A) 
PMN bind opsonized  L. pneumophila. PMN were incubated with L. pneumophila in  the presence  of 
fresh immune human  serum  for 30 min at 37°(3 on a gyratory shaker  and centrifuged onto glass 
slides. The PMN-associated bacteria were stained with fluorescein-conjugated  rabbit anti-L,  pneu- 
mophila antiserum and the cells were examined by fluorescence  microscopy.  ×  1,400. (B) and  (C) 
PMN  ingest  opsonized  L. Oneumophila. PMN and L. pneumophila were  incubated as  in  A, fixed  in 
glutaraldehyde and osmium, and processed  for electron  microscopy.  (B) PMN with three intracel- 
lular L. pneumophila bacteria  (arrows).  (×  11,580). (3. The bacterium at  the lower portion of the 
PMN shown in B is seen at higher magnification to be enclosed within a membrane-bound vacuole 
X 41,690. 
antiserum,  but  we obtained  similar results  when  we used  immune  human  serum.  In 
the presence  of fresh  normal  serum  and  antibody,  PMN  failed to kill L. pneumophila 
effectively. Under  these  same  conditions,  PMN  reduced  CFU  of E.  coli  by  2.5  logs. 
(PMN  require  both  antibody  and  complement  to kill E.  coli  [2];  both  are present  in 
fresh normal human  serum, which contains low levels of natural  antibody against  this 
strain  of E.  coli  [2].)  When  the E.  coli and  L. pneumophila were mixed together  in  the 
same test  tube,  PMN  killed the E. coli as effectively as when  the E.  coli were present 
alone,  indicating  that  the  killing  capacity  of  PMN  was  not  reduced  in  cultures 
containing L. pneumophila. 
L. pneumophila Resists PMN Killing Even after the Bacteria  are PMN-associated.  When 
PMN  are incubated with L. pneumophila in the presence of antibody and complement, 
they  bind  or  ingest  nearly  all  the  bacterial  cells  (Table  II);  however,  most  of the MARCUS  A.  HORWITZ  AND  SAMUEL  C.  SILVERSTEIN  393 
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Fla.  2.  PMN  require both antibody and complement to kill any L. pneumophila. PMN  (5  X  l0  s) 
and 2.5  X  10  s CFU  of L. pneumophila were incubated at  37°C in  5% CO2-95%  air on  a ~ratory 
shaker for 2 h in 0.9 ml medium (final volume) containing 10% fresh normal human serum (with an 
[FA  anti-L, pneumophila titer of <1:64)  or  10% fresh  immune  human  serum  (with  an  [FA anti-L. 
pneumophila tlter of 1:4,096).  In some tubes, the sonicates from 5 X  l0  s PMN or buffer were added 
as controls for intact  PMN.  CFU in each  tube were determined  initially  and  at  the end  of the 
incubation. Each point represents the average for four replicate tubes -1- SE. 
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Fio.  3.  L. pneumophila  resists  killing by PMN under conditions in which PMN effectively  kill  a 
serum-resistant encapsulated strain of E. coli. PMN (2.5 ×  l0  n) and 5 ×  l0  b CFU of L. pneumophila 
and/or E. coli were incubated at 37°C for 1 h on a gyratory shaker in 0.9 ml medium (final  volume) 
containing 10% fresh normal human serum (NS) alone or 10% NS plus 8.5 agglutinating units/ml 
of dialyzed rabbit anti-L, pneumophila antiserum (Aha-L.p.). CFU of E. coil and L. pneumophila were 
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bacterial cells from egg yolk-grown cultures are nonviable (6). Thus, from the studies 
described  in Table  II, we did  not know whether PMN,  in the presence of antibody 
and complement, bind or ingest that small minority of bacterial cells that are viable. 
We undertook this study to clarify this issue, and to determine whether the resistance 
ofopsonized L. pneumophila to PMN killing is a result of a failure of PMN to bind the 
viable  bacteria or of a  failure of PMN  to kill these bacteria after binding them. We 
incubated  PMN  with  L. pneumophila for  varying  periods  of time,  separated  PMN- 
associated and nonassociated L. pneumophila by differential centrifugation, and deter- 
mined the number of CFU in each fraction. 
When  we  incubated  PMN  and  L.  pneumophila together  in  the  presence  of both 
antibody  and  complement  (fresh  immune human  serum)  (Fig.  4B),  PMN  killed  a 
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FIc.  4.  Failure of PMN to kill L. pneumophila effectively:  (A) In the absence of antibody, PMN fail 
to bind L. pneumophila and, subsequently, to kill the bacteria.  (B) In the presence of antibody, PMN 
rapidly bind L. pneumophila but nevertheless fail to kill a  large proportion of the bacteria.  PMN (5 
X  106) were incubated in plastic tubes with 5 X  l0  s CFU of L. pneumophila in 0.9  ml media  (final 
vol) that contained  10% fresh normal human serum (A) or 10% fresh immune human serum (B) at 
37°C in 5% CO2-95%  air on a gyratory shaker for 0,  l, 2, or 4 h. (in the experiment depicted in (B) 
one set of control tubes [dashed line]  contained normal serum instead of immune serum.) At each 
time point, the contents of some replicate tubes were immediately assayed for the total number of 
CFU in each tube after lysing the PMN by sonication (Unfractionated samples). The contents of 
other  replicate  tubes  were  first  centrifuged  to  separate  PMN-associated  and  nonassociated  L. 
pneumophila, as described in Materials and Methods; each of these fractions was then sonicated and 
assayed for the total number of PMN-associated CFU and nonassociated CFU of L. pneumophila. 
The points on the lines labeled Sum of PMN-associated and nonassociated are the mathematical 
sums of the experimentally determined  values for PMN-associated and nonassociated GFU of L. 
pneumophila at each time point. Each point on the lines labeled Unfractionated represents the average 
for two replicate tubes ±  SE.  Each point on the lines  labeled  PMN-associated and nonassociated 
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limited proportion of the L. pneumophila and most  (>75%)  of the surviving bacteria 
were PMN-associated after 1 h of incubation. The additional reduction in CFU of L. 
pneumophila that occurred between 1 and 4 h after the start of the incubation appeared 
to result primarily from the death of PMN-associated bacteria. Thus, the resistance 
of opsonized L. pneumophila to PMN killing was a result of the failure of PMN to kill 
bacteria that were associated with them. 
In contrast, when we incubated PMN and L. pneumophila together in the presence 
of only complement  (fresh normal human serum)  (Fig. 4 A), nearly all  (93%)  of the 
CFU of L. pneumophila failed to associate with PMN and, as expected from previous 
results  (Fig.  2),  PMN did  not  kill L. pneumophila under  these conditions.  Thus,  the 
complete resistance of L. pneumophila to PMN killing in the absence of antibody was 
a result of a  failure of PMN to bind these unopsonized bacteria. 
PMN Do Not Support the Growth of L. pneumophila.  To determine whether PMN, like 
monocytes, support  the growth of L. pneumophila (1,  7),  we incubated L. pneumophila 
with PMN in the presence of normal or immune serum on a  gyratory shaker for 1 h, 
and without shaking thereafter, and determined CFU daily. L. pneumophila failed to 
multiply under either of these conditions. 
Because PMN are relatively short-lived in comparison to monocytes, we repeated 
the  experiment just  described  except  we  added  fresh  PMN  and  either  normal  or 
immune human serum to the cultures daily. After adding fresh cells and serum, we 
incubated  the  cultures  on  a  gyratory shaker  for  1  h  and  then  returned  them  to 
stationary incubation  for the remainder of the day. L. pneurnophila did not multiply 
under these conditions either. 
Discussion 
Our experiments show that virulent egg yolk-grown L. pneurnophila are completely 
resistant to the bactericidal effects of human serum even in the presence of high-titer 
rabbit or human anti-L, pneumophila antibody. In contrast, agar-adapted L. pneumophila 
have been reported to be sensitive to serum  (8).  Egg yolk-grown and agar-adapted 
bacteria differ in that agar-adapted bacteria are avirulent  for guinea pigs and eggs, 
whereas egg yolk-grown bacteria cause lethal  infections  in both.  In their virulence, 
egg yolk-grown L. pneumophila more closely resemble a human pathogen than do agar- 
adapted bacteria. Consequently,  we suggest that L. pneumophila that are pathogenic 
for man are also serum resistant. 
Antibody is required  to fix complement to L. pneumophila and only complement- 
coated  bacteria  are  efficiently  bound  to  or  ingested  by  PMN.  In  this  respect,  L. 
pneurnophila resembles encapsulated E. coli, an extracellular pathogen (2). The similar- 
ity ends  here,  however,  because complement-coated E.  coli are efficiently killed  by 
PMN but complemented-coated L. pneumophila are not. A significant proportion of L. 
pneumophila resist  killing  by PMN  even  after the  bacteria  are  bound  to  the  PMN 
surface by phagocytosis-promoting ligands. 
The capacity of L. pneumophila to resist  completely killing by human  serum  and 
PMN  in  the  absence  of antibody  likely  contributes  to  its  pathogenicity  for  man. 
Because  L.  pneumophila are  completely  resistant  to  serum  even  in  the  presence  of 
antibody,  the degree to which  antibody influences pathogenicity probably depends 
on how antibody affects the interaction of L. pneumophila with PMN and monocytes. 
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are killed but a significant proportion survive the encounter. Consequently, the critical 
questions  regarding  the  influence  of antibody  on  pathogenicity  may  be  whether 
antibody influences the interaction of L. pneumophila with monocytes and, especially, 
whether antibody alters the capacity of L. pneumophila to multiply within monocytes. 
These questions are addressed in an accompanying paper (7). 
Summary 
We have previously reported  that  virulent  egg yolk-grown Legionella pneumophila, 
Philadelphia  1 strain, multiplies intracellularly in human blood monocytes. We now 
report on  the interaction  between  virulent  L. pneumophila and  human  polymorpho- 
nuclear leukocytes (PMN), antibody, and complement, in vitro, under antibiotic-free 
conditions. 
L.  pneumophila in  concentrations  ranging  from  103  to  106  colony  forming  units 
(CFU)/ml are completely resistant  to the bactericidal effects of 0-50% fresh normal 
human serum, even in the presence of high concentrations of rabbit or human anti-L. 
pneumophila antibody. 
L.  pneumophila bacteria  fix  the  third  component  of  complement  (C3)  to  their 
surfaces, as measured by fluorescence microscopy using rhodamine-conjugated  goat 
anti-human C3 IgG, only when the bacteria are incubated with both specific anti-L. 
pneumophila antibody and complement. Similarly, L. pneumophila adhere to PMN, as 
measured by fluorescence microscopy, only in the presence of both specific antibody 
and  complement.  Electron  microscopy revealed  that  these  opsonized  bacteria  are 
phagocytosed by the PMN. 
PMN  require  both  antibody  and  complement  to  kill  L.  pneumophila; even  then, 
PMN reduced CFU of L. pneumophila by only 0.5 log under conditions in which they 
reduce  CFU  of a  serum-resistant  encapsulated  strain  of Escherichia coli by 2.5  logs. 
Separation of PMN-associated and nonassociated CFU of L. pneumophila revealed that 
the  major  proportion  of  the  surviving  bacteria  are  PMN  associated.  Thus,  the 
ineffective killing of opsonized L. pneumophila is a  result of a  failure of PMN  to kill 
these bacteria after they become PMN-associated.  With or without  antibody, PMN 
do not support the growth of L. pneumophila. 
These findings suggest that PMN, even in conjunction with the humoral immune 
system,  do  not  play  a  decisive  role  in  defense  against  the  Legionnaires'  disease 
bacterium. 
We thank Ms.  Darragh Kelvie for excellent  technical  assistance,  and  Ms. Judy Adams for 
preparing the electron microscopy specimens and printing the photographs in this paper. 
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